Skip to main content

Market Overview

Study Reports Some Cases Of Delayed Rash After Moderna COVID-19 Vaccine Dose: Report

Share:
  • According to a New England Journal of Medicine report, some people experienced delayed skin rashes after receiving Moderna Inc’s (NASDAQ: MRNA) COVID-19 shot, writes Bloomberg.
  • Researchers reported details on 12 cases of reactions that appeared eight or more days after the first dose.
  • In some cases, the rashes were four inches wide or more and took around six days to resolve.
  • According to the study, most of the delayed reactions developed on the shoulder and upper arm near the injection site, while others appeared on the elbow, fingers, and palm.
  • In some cases, the tissue below the skin surface hardened and lost its smooth appearance in response to the inflammation.
  • The rashes were mostly treated with ice and antihistamines, although some patients needed steroid treatments.
  • About half also got skin reactions after the second dose, though less severe.
  • The delayed reactions to the Moderna vaccine are different from the immediate injection-site reactions common with both the Pfizer Inc (NYSE: PFE) and Moderna messenger RNA vaccines, said Kimberly Blumenthal, co-director of the clinical epidemiology program at Massachusetts General Hospital in Boston.
  • “This is a Moderna-specific reaction that pops up after the first week and can last a number of days.” “I have not been told about any from Pfizer,” Blumenthal said.
  • Price Action: MRNA shares are trading 1.54% lower at $129.2 in premarket trading on the last check Thursday.
 

Related Articles (PFE + MRNA)

View Comments and Join the Discussion!

Posted-In: Bloomberg COVID-19 VaccineBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com